ATTACHMENT B - 2010 Renewal

Voluntary Questions Added to the Data Collection Over Time:

These were approved at the initial implementation of the project- 2001.

- Respondents will be asked not only to report deaths and serious injuries to FDA (as they are
 required to do under the statute), but will also be asked to voluntarily report if an event resulted in
 minor injury to the patient or if an event had the potential for patient harm (including "close-call")
 events.
- Rationale: Both facilities and FDA wish to become more proactive in improving patient safety. If reports are only received after someone has been seriously injured or has died as a result of a medical-device-related event, it is too late to help the injured person. By obtaining information that a potential hazard exists before a serious consequence has occurred, FDA will be able to alert the health care community as to potential problems so that patient safety may be promoted. User facilities will be able to view redacted "potential for harm" events that have been reported into the system in the newsletter that is provided to them. The facilities will be able to learn from the reported events, and can take steps to avoid similar problems in their own facilities.
- If the facility checks that the event took place in the hospital, they are then asked to fill in this voluntary question: "Area in the hospital where the event took place" (they are given choices).
- In D4 on the 3500A it asks for the operator of the device, then gives choices of (health professional) (lay user/patient) (other). This is not very helpful to FDA in deciding what "type" of person had trouble with the device, so we asked for more detail in this voluntary question: "Who was operating the device: (doctor) (allied health professional) (patient) (nurse) (family member/visitor) (other)"

These questions were approved in 2001, but have been discontinued because the sites either were not routinely answering them, were confused by them, or the answers were found, over time, not to be helpful to FDA.

- What time of day did the event occur?
- Has the facility discontinued use of the device due to the adverse event? (this is a yes or no response).
- Check all of the factors you think may have contributed to the event:

o madequate systems
○ Poor device design
○ Poor device maintenance
○ Inadequate equipment
o Unfamiliarity with device
○ Training
Unfamiliar environment (clinician)
Other:
• Check all of the factors you think could prevent future occurrences of this type of event:
○ New or improved devices
○ Additional equipment:
Better device maintenance
○ Appropriate training
Other:

These were approved in 2004 by Memo

Additional questions about in-vitro diagnostic products added to the MedSun form:

Did the problem involve (check all that apply):

1. 2	The reagent? The instrument?
3.	Single use test?
4.	Something else? (specify)

Is this a recurrent problem with this assay, test kit, or instrument?

1.	Yes	
2.	No	

Additional comments	
Which of the following problems did you obse comments as needed)	rve? (Check all that apply and include additional
1. Calibration	9. Inadequate/unclear instructions for use
Product not available to return to manufacturer 9. Discontinued all use of product	

Please describe any follow-up actions below (check all that apply and include additional comments as needed):

1.	Repeated assay, results OK,
	reported out
2.	Repeated assay, still problems
3.	Replaced reagents
4.	Opened new lot
5.	Manufacturer notified
6.	Called for service
7.	Product returned to manufacturer
	(Date of return: / /)
Additiona	al Comments

8.		duct not available to return to manufacturer
9.		continued all use of product
		known
		applicable
12.	Oth	er (specify):
Th	ese '	were approved in 2006, by Memo
Thes	_	estions were added to gain more information about tissue and cell
1. Tra	nspla	nt Product Distinct Identification Code (or other identifiers)
		e any pre-implant problems that were found with the human cell or tissue (Check all that apply)
prode		No problem was detected with the product.
	•	No problem was detected with the product.
	_	Product damage, describe
	€	Packaging problem, describe
	€	Product contamination, describe
	€	Labeling problem, describe Product Irregularity, describe
	€	Other
2 147	- 4l-	
		e human cell or tissue manipulated following removal from the packaging
prior		ransplantation?
	€	Yes. Please describe (e.g., stretched, rinsed in saline):
	€	No (SKIP TO 4)
		Unknown (SKIP TO 4)
4. Was	s a pr	e-transplant gram stain of the tissue performed?
		Yes, pre-transplant gram stain was performed.
	€	No, pre-transplant gram stain was not performed. (SKIP TO 5)
		Do not know (SKIP TO 5)
	€	Other (Specify)
	42	The gram stain result was:
		Negative for organisms
		Positive for organisms: RESULT
	€	Unknown
	€	Other (Specify)

5. Was a pre-implant <u>culture</u> performed?			
€ No, pre- € Unknow	-implant culture was performed implant culture was not performed (SKIP to 6) m (SKIP to 6) Specify)		
	rre showed: th of organisms growth of organism(s). Identification of organism:		
€ Unknow € Other (S	Specify)		
6. Was the cell or	tissue product actually used (transplanted or infused)?		
□ Not know	used (Skip to 8)		
7. Date of Transplan	t/Infusion// mm/ dd/ yyyy		
=	ces transplanted with the tissue? Ease provide information in the DEVICE section of the MedSun		
9. Post-Transplan Was there a post-trans	at Adverse Event plant adverse event or close call?		
€ Yes, adverse event € Yes, potential adve	erse event (or close call)		
€ No (Please skip to e	and to record any additional comments.)		
10. For <u>Infection</u> (□ Check here if there	Related Events was not an infection-related adverse event and skip to 11.)		
	ılts (post-transplant):		
Anatomic Site Results	Date// mm/ dd/ yyyy		
Anatomic Site Results	Date/ mm/ dd/ yyyy		
Anatomic Site	Date/ mm/ dd/ yyyy		

10b. Other Study Results:			
Test	Date//Resu	ults	
Test	Date/Resu	ults	
Test	Date/Resu	ults	
12. M € € € € €	Antibiotics for prophylaxis Antibiotics for treatment Required hospitalization	he Event (Check all that apply) atient already hospitalized	
€	€ Unknown		
€ Other (Specify)			
Any Additional Comments:			
Profile Information asked of hospitals			

- Is facility teaching hospital?
 Bed size: up to 100 100-300
 Region of country
 Acute or tertiary 300-500 500+